Crossmark

Engineered CRISPR-Cas12a for higher-order combinatorial chromatin perturbations

Crossref DOI link: https://doi.org/10.1038/s41587-024-02224-0

Published Online: 2024-05-17

Published Print: 2025-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hsiung, C. C.-S. https://orcid.org/0000-0002-1366-6069
Wilson, C. M. https://orcid.org/0000-0002-2553-4151
Sambold, N. A.

Dai, R.

Chen, Q.

Teyssier, N.

Misiukiewicz, S.

Arab, A. https://orcid.org/0000-0002-0024-2937
O’Loughlin, T. https://orcid.org/0000-0002-4783-2352
Cofsky, J. C. https://orcid.org/0000-0001-5403-8555
Shi, J. https://orcid.org/0000-0002-8427-6316
Gilbert, L. A. https://orcid.org/0000-0001-5854-0825
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (R01HG012227)

U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (UM1HG012660)

U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (K01HG012789)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (DP2CA239597)

Laboratory for Genomics Research

MARK FOUNDATION FOR CANCER RESEARCH

Helen Hay Whitney Foundation
License Information

Text and Data Mining valid from 2024-05-17

Version of Record valid from 2024-05-17
More Information

Article History

Received: 9 January 2023

Accepted: 28 March 2024

First Online: 17 May 2024

Competing interests

: C.C.H., C.M.W., R.D. and L.A.G. have filed patent applications related to multiAsCas12a. J.S. is a scientific consultant for Treeline Biosciences. L.A.G. has filed patents on CRISPRoff/on and CRISPR functional genomics and is a co-founder of Chroma Medicine. The other authors declare no competing interests.

Document is current

Any future updates will be listed below